This inventor holds 1 USPTO granted patent, plus 1 CIPO patent. Top assignee: Mankind Pharma Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Mahadev Bandgar - Innovator in Selective JAK1 Inhibition
Introduction
Mahadev Bandgar is a notable inventor based in Haryana, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit Janus kinase 1 (JAK1). His work is crucial in advancing treatments for various diseases.
Latest Patents
Mahadev Bandgar holds a patent for "Compounds for inhibition of Janus kinase 1." The objective of this invention is to provide compounds that act as selective JAK1 inhibitors. The patent also includes a process for the preparation of these inhibitors, a composition containing the compounds, and their utility in medical applications. He has 1 patent to his name.
Career Highlights
Currently, Mahadev Bandgar is associated with Mankind Pharma Ltd., a prominent pharmaceutical company in India. His role involves research and development, focusing on innovative solutions to enhance therapeutic efficacy.
Collaborations
(Section skipped due to space constraints.)
Conclusion
Mahadev Bandgar's contributions to the field of selective JAK1 inhibition highlight his innovative spirit and dedication to advancing medical science. His work continues to pave the way for new therapeutic options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile